Tirzepatide Price in the UK: The Honest Picture

The myth: a lower tirzepatide price means a better deal

A question our prescribers hear most weeks goes something like this: "I've seen it cheaper elsewhere, is it the same medicine?" It's a fair thing to ask. The honest answer is that the medicine itself, dispensed through the licensed UK supply chain, is the same. What changes at a lower price is usually what surrounds it.

Private tirzepatide prices in the UK are quoted per pen, with each pen covering four weekly doses. Eli Lilly raised the UK list price in September 2025, and since then the going rate for Mounjaro across the private market has settled into a range of roughly £149 to £375 per month, depending on dose and provider. Those figures are widely reported and should be treated as background context, not guarantees, individual providers set their own prices and the market keeps moving. For a closer look at how the cost breaks down across starting doses, the tirzepatide cost overview covers the full picture.

The point is this: a headline price that looks low rarely tells you what a clinical assessment costs on top, whether delivery is included, or whether aftercare is available if you have questions mid-treatment. Price is the easy thing to compare. The rest takes a bit more digging.

What a headline tirzepatide price commonly leaves out

Not every quoted price is all-in. Some services charge separately for the initial consultation. Others add a prescription fee. Delivery (especially tracked, temperature-appropriate delivery for a refrigerated injectable) is frequently billed as an extra. And aftercare, meaning access to a prescriber if side effects appear or your dose needs reviewing, can be absent entirely from budget options.

This matters because tirzepatide is a medicine that typically starts at 2.5mg and is titrated upward by the prescriber over several months, usually in four-week steps. Each dose stage may carry its own price (see what the 2.5mg starting pen costs and how 5mg pricing compares) and the total cost of a course of treatment is the relevant number, not the entry-level pen alone. A service that looks affordable at 2.5mg may become expensive once consultation fees, prescription fees and delivery are added per order.

The NICE appraisal of tirzepatide, TA1026 published in December 2024, sets out the clinical framework within which this medicine is assessed. Good private services follow the same evidence base; their pricing should reflect the clinical work involved, not undercut it.

What nume's price actually covers

At nume, the price you see covers everything. One figure, one payment, nothing added at checkout. That means the consultation, the prescription, the treatment itself, and next-working-day tracked delivery by DPD in plain packaging. Aftercare is included (a prescriber is available seven days a week) and every repeat order is clinically reviewed again before it goes out. There is no subscription and no auto-renewal.

We are not the cheapest option in this market, and that is a deliberate choice. The way we operate requires a GPhC-registered pharmacy, a named prescriber reading every consultation personally, photo-ID verification, live weight verification on video, and GP notification in line with GPhC guidance. None of that is free to run. Our weight-loss treatment page sets out the full service, and current treatment pricing is shown on the consultation and treatment hub.

If you want to compare the range of tirzepatide prices in more detail, the how much is tirzepatide page gives a fuller breakdown. And if you've seen a price that seems significantly below the market range, the section below is worth reading first.

Why cheapest is the wrong question to ask about a prescription medicine

Tirzepatide is a Prescription-Only Medicine. The MHRA has documented fake weight-loss pens sold through social media and unverified websites, some containing the wrong substance entirely, causing hospitalisations. In 2025 alone, enforcement operations seized around 20 million doses of illegally traded weight-loss medicines, worth an estimated £45 million, and the first illicit UK manufacturing site producing counterfeit tirzepatide pens was identified. The MHRA's Yellow Card scheme allows anyone to report a suspected fake seller.

Sellers offering tirzepatide at prices that sit well below the market range, particularly without requiring a clinical consultation, are a red flag. The question to ask is not "who is cheapest?" but "who can I verify?". Any legitimate online pharmacy is listed on the GPhC register, which is searchable and public. nume's GPhC premises registration number is 9012878, verifiable there directly.

For people curious about whether a cheaper alternative exists through a different route, the cheap tirzepatide page explains what cheap usually means in practice. Tirzepatide dispensed through the licensed UK supply chain, by a regulated pharmacy following a genuine clinical assessment, has a floor below which the price cannot honestly go. Anything beneath it should prompt a question, not a click.